Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Selected papers from 2020 5th International Conference on Pharmacy and...
share announcement

Selected papers from 2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 14216

Special Issue Editors

Prof. Yusnita Rifai

E-Mail
Guest Editor
Department of Pharmacy, Hasanuddin University, Makassar, Indonesia
Interests: drug discovery, including exploring natural product chemistry and drug synthesis
Prof. Dr. Nagendra Kumar Kaushik

E-Mail Website
Guest Editor
Department of Electrical and Biological Physics, Plasma Bioscience Research Center, Kwangwoon University, Seoul 01897, Republic of Korea
Interests: plasma medicine; biophysics; biomaterials; nanotechnology; nanomedicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020) is the premier forum for the presentation of new advances and research results in the fields of theoretical, experimental, and applied Pharmacy, and Pharmaceutical Science and Biomedical Sciences. The special issue will bring together leading researchers, engineers and scientists in the domain of interest from around the world.

This Special Issue, “Special Issue of 2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020)”, will mainly focus on pharmaceutics, nanotechnology; cosmetology; Drug Delivery Systems, clinical research and clinical trials and other related biomedical areas. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

ICPPS 2020 welcomes paper submission including abstract and full paper which is not published elsewhere. Topics of interest for submission include, but are not limited to:

  • Pharmaceutics
  • Drug Delivery Systems
  • Medicinal Chemistry, Pharmacology, Organic Chemistry
  • Nanotechnology
  • Drugs and Medical Devices: Regulatory Affairs
  • Pharmacy Business and Market
  • Radiopharmaceuticals
  • Nanotechnology in Pharmaceuticals
  • Novel Drug Delivery Systems
  • Bioavailability and Bioequivalence Studies
  • Clinical Research and Clinical Trials
  • Medical Biotechnology
  • Pharmaceutical Botany
  • Biopharmaceutics and Pharmacokinetics
  • Cosmetology
  • Radiopharmacy

A 10–20% discount is provided for publication in the Special Issue for all the attendees of the ICPPS 2020.

Prof. Yusnita Rifai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pharmaceutics
  • Radiopharmaceuticals
  • Nanotechnology
  • Cosmetology
  • Drug Delivery Systems
  • Biomedical Sciences

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 7689 KiB  
Review
Utility of Reactive Species Generation in Plasma Medicine for Neuronal Development
by Sarmistha Mitra, Neha Kaushik, Il Soo Moon, Eun Ha Choi and Nagendra Kumar Kaushik
Biomedicines 2020, 8(9), 348; https://doi.org/10.3390/biomedicines8090348 - 12 Sep 2020
Cited by 11 | Viewed by 4616
Abstract
Reactive oxygen species (ROS) are critical signaling molecules for neuronal physiology that stimulate growth and development and play vital roles in several pathways when in a balanced state, but they cause neurodegeneration when unbalanced. As ROS levels above a certain threshold cause the [...] Read more.
Reactive oxygen species (ROS) are critical signaling molecules for neuronal physiology that stimulate growth and development and play vital roles in several pathways when in a balanced state, but they cause neurodegeneration when unbalanced. As ROS levels above a certain threshold cause the activation of the autophagy system, moderate levels of ROS can be used as treatment strategies. Currently, such treatments are used together with low-level laser or photodynamic therapies, photo-bio modulation, or infrared treatments, in different chronic diseases but not in the treatment of neurodegeneration. Recently, non-thermal plasma has been successfully used in biomedical applications and treatments, and beneficial effects such as differentiation, cell growth, and proliferation, stimulation of ROS based pathways have been observed. Besides the activation of a wide range of biological signaling pathways by generating ROS, plasma application can be an effective treatment in neuronal regeneration, as well as in neuronal diseases. In this review, we summarize the generation and role of ROS in neurons and provide critical insights into their potential benefits on neurons. We also discuss the underlying mechanisms of ROS on neuronal development. Regarding clinical applications, we focus on ROS-based neuronal growth and regeneration strategies and in the usage of non-thermal plasma in neuronal and CNS injury treatments. Full article
(This article belongs to the Special Issue Selected papers from 2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020))
►▼ Show Figures

Figure 1

28 pages, 7413 KiB  
Review
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
by Sandra Rodríguez, Andrés Muñoz, Rosa-Helena Bustos and Diego Jaimes
Biomedicines 2020, 8(9), 303; https://doi.org/10.3390/biomedicines8090303 - 23 Aug 2020
Cited by 3 | Viewed by 8604
Abstract
Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour [...] Read more.
Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1, and the modulation of cell-mediated immunity (B cells and T cells) by anti CD20 or anti CTAL-4 agents, and can increase the risk of associated infections or adverse events (AE). In this context, the entry of biotherapeutics represented a challenge for pharmacovigilance, risk management and approval by the main global regulatory agencies regarding biosimilars, where efficacy and safety are based on comparability exercises without being an exact copy in terms of molecular structure. The objective of this review is divided into three fundamental aspects: (i) to illustrate the evolution and focus of pharmacovigilance at the biopharmaceutical level, (ii) to describe the different approved recommendations of biopharmaceuticals (biological and biosimilars) and their use in rheumatic diseases (RDs) such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and other less frequent RD like cryopyrin-associated autoinflammatory syndromes (CAPS), and (iii) to identify the main AE reported in the post-marketing phase of RD biopharmaceuticals. Full article
(This article belongs to the Special Issue Selected papers from 2020 5th International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2020))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop